Background: Accumulation of the cytosine arabinoside (ara-C) metabolite ara-C-triphosphate (ara-CTP) in leukemic blast cells is considered to be the main determinant of ara-C cytotoxicity in vitro and in vivo. Retinoids such as a//-?ra«.s-retinoic acid (ATRA) have been shown to increase the sensitivity of acute myelogenous leukemic (AML) blast cells to ara-C. To investigate the mechanism of this sensitisation, the hypothesis was tested that ATRA augments cellular ara-CTP levels in human-derived myelogenous leukemia HL-60 cells.
Introduction
Cytosine arabinoside (ara-C) is one of the most effective compounds in the treatment of pediatric and adult acute myelogenous leukemia (AML). Yet success of treatment with ara-C is often confounded by development of drug resistance. Mechanisms of resistance against ara-C may involve any of the many metabolic steps germane to the toxification pathway of ara-C to the nucleotide ara-C-triphosphate (ara-CTP) [1] . Strategies to increase therapeutic efficacy and to overcome ara-C resistance have hitherto focussed primarily on the enhancement of cellular accumulation and retention of ara-CTP, because a close correlation was found between these parameters and ara-C cytotoxicity [2] [3] [4] or clinical response [5] [6] [7] [8] [9] [10] . Feedback inhibition by ara-CTP of the toxifying enzyme deoxycytidine kinase obstructs any further increase of ara-CTP levels even when combination treatments with ara-C and pharmacological modulators have been optimised [11] . The most effective modulators of ara-C cytotoxicity are the ribonucleotide inhibitors arabinosyl-2-fluoroadenine (F-Ara-A) [11] [12] [13] [14] , 2-chlorodeoxyadenosine (2-CdA) [15] and hydroxyurea (HU) [16] [17] [18] . Pretreatment of leukemia patients with these drugs results in 2-3-fold increases of ara-CTP accumulation. Combinations of ara-C with F-Ara-A or 2-CdA are currently in clinical phase I and II evaluation [12, 15] . A more recent approach is based on the observation that drug sensitivity of AML blasts to ara-C can be augmented by antisignalling drugs and growth regulators such as haematopoietic growth factors and retinoic acids [19] [20] [21] .
/4//-/ra/?.y-retinoic acid (ATRA), a vitamin A derivative, induces cellular differentiation in several hematological precursor cell lines and in blast cells from patients with acute promyelocytic leukemia (APL) [22] [23] [24] . Induction of differentiation is the result of modulation of gene expression via interaction with retinoic acid receptor (RAR, RXR) transcription factors. Since clinical studies have demonstrated the efficacy of ATRA in the treatment of APL the drug is currently under investigation as a component of adult and pediatric APL treatment protocols [25] [26] [27] . Furthermore, ATRA was shown to reduce the expression of the antiapoptotic protooncogen bcl-2 and to increase ara-C cytotoxicity [28, 29] . We wished to test the hypothesis that changes in ara-C metabolism are involved in the increase of ara-C efficacy by ATRA.
Materials and methods

Drugs
Ara-C, all-trans-reUnoic acid and /i-c/j-retinoic acid, nucleotides and ara-CTP were obtained from Sigma Chemical Co (Deisenhofen, Germany). Ara-C was dissolved in sterile water; retinoid stock solutions were prepared in ethanol and stored at -20 °C. Directly before use, the stock solutions were diluted in RPMI 1640 cell culture medium. The final concentration of ethanol in the culture did not affect cell growth. All the procedures involving retinoids were performed under subdued light to avoid photoisomerisation.
Cell lines
The human acute myeloid leukemic cell line HL-60, originally described by Gallagher [30] , and the K-562 cell line, derived from a patient with chronic erythroleukemia [31] , were obtained from the European Collection of Cell Cultures (Salisbury, UK) and mycoplasma-screened. HL-60 cells are described as retinoic acid-sensitive, K-562 cells as retinoic-acid-resistant [32] .
Cells were maintained in suspension culture at exponential growth phase in RPMI 1640 (Gibco, UK), supplemented with 10% heatinactivated fetal calf serum (Gibco, UK) under standard conditions with 5% CO 2 . Cells were used no longer than six weeks. The number of viable cells was determined using a hemocytometer after staining with trypan blue.
Measurement of ara-CTP
Exponentially growing cells (3-5 x 10 5 /ml) were preincubated with ATRA or 13-cis-retinoic acid for 24 and 72 hours. Cells were washed, resuspended in ara-C containing medium and incubated in a shaking water bath at 37 °C for one hour. Following incubation, the cells were washed twice in ice-cold phosphate-buffered saline (pH 7.2) and the number of viable cells was determined. Ara-CTP was separated from other nucleotide triphosphates by an isocratic ion pair high performance liquid chromatography (HPLC) method (RI C, 8 column, uv detection 270 nm; quantification against internal standards). Incubation and control experiments were carried out in triplicates and repeated at least three times [33] 
M T T assay
The effect of drug combinations on HL-60 cell growth and viability was determined using the 3-(4,5 dimethylthiazol-2-yl-)5 diphenyltetrazolium bromide (MTT) assay [34, 35] . Briefly, HL-60 cells (10 5 ) were seeded in 96 multi-well plates (Nunc, Naperville, USA) and incubated with drugs for 24 hours. Cells were centrifuged at 800 g for five minutes, washed twice in phosphate-buffered saline and resuspended in a solution of MTT (5 mg/ml RPMI 1640). After incubation for four hours, cells were again washed and the formazan crystals were dissolved in DMSO. Optical density was measured at 540 nm using a platereader (Labsystems iEMS Reader MF). Experiments in octuplets were carried out three or more times. Potential chemical interactions between retinoids and MTT were checked in incubates with non-viable cells [36] .
Markers of apoptosis
Gel electroplwresis and DNA fragmentation
Agarose gel electrophoresis was used to detect DNA laddering in whole cells (I0 6 cells/ml) [37] . Following four-hour drug treatment, cells were centrifuged at 90 g for 10 min at 4 C and resuspended in RNase A solution (17 mg/ml) After 20 minutes at room temperature, cells were mixed with a gel loading solution (Sigma Chemical Co) and loaded onto a running gel (agarose 1.8%, TBE 0.5); the digestion gel contained agarose 0.8%, proteinase K 1.2 mg'ml and TBE 1 (EDTA 0.5 M 25 ml, pH 8; tris 54 g; boric acid 27.5 g; aqua dest. 4.975 I). Cells were preincubated with ATRA (0.01-1 uM) for 24 or 72 hours, followed by one-hour incubation with 10 uM ara-C. Values are the mean ± SD of three experiments, each conducted in triplicate. Decrease of ara-CTP levels compared to control set to 100% was significant for all experiments (P < 0.05).
Flow cytomelry
In order to quantitate hypodiploid cells (sub-Gl peak) the DNA histogram was measured as described by Ormerod et al. [38] .
Cell shrinkage
Cell size was analysed with a Casy 1 cell counting and sizing system (Schaerfe System, Reutlingen, Germany) using a 150 urn aperture for routine analysis. Mean cell volume of untreated HL-60 cells was 1070 fl [39] . All experiments on apoptosis were carried out at least three times.
Statistical analysis
Intracellular ara-CTP concentrations and proliferation kinetics with and without preincubation with retinoic acids were compared using the Kruskal-Wallis One Way Analysis of Variance on Ranks. To isolate the groups which differed from the others we used the Dunn's All Pairwise Multiple Comparison Procedure. Differences in cytotoxicity and apoptosis between experimental conditions were evaluated using paired Student's /-test.
Results
Effects of retinoids on cellular levels of ara-CTP
After incubation of ara-C 10 uM for one hour the mean intracellular ara-CTP concentration was 388 ± 111 pM/10 7 HL-60 cells (n = 60). Following 24-hour preincubation with ATRA (1, 0.1 or 0.01 uM), ara-CTP levels generated from ara-C (10 uM, one hour) in HL-60 cells were significantly decreased to 63% ± 12%, 73% ± 1 1 % and 76% ± 10%, respectively (P < 0.05). Preincubation with ATRA (1 uM) for 72 hours further decreased ara-CTP levels to 41% ± 4% (Figure 1 ). Like ATRA, the retinoic acid isomer /5-cw-retinoic acid 1 uM decreased ara-CTP accumulation in HL-60 cells to 62% ± 8% after 24 hours and 38% ± 8% after 72 hours.
In K-562 cells, which are known not to undergo retinoic acid-induced differentiation [32] , ara-CTP levels were not altered by preincubation with ATRA or 13-cisretinoic acid. 
Effect of ATRA on ara-C-induced cytotoxicity and apoptosis
The effect on cell growth and viability of combining ara-C with ATRA was determined using the MTT assay. The IC50 values for the single agents in HL-60 cells amounted to between 5 and 10 uM for ara-C and between 10 and 100 uM for ATRA. ATRA at concentrations of 1 uM and below did not affect cell growth. Coincubation of ATRA (0.1-10 uM) with ara-C (0.1 and 10 uM) resulted in supra-additive cytotoxicity (Figure 2) . Ara-C 2 uM and ATRA 50 uM were incubated with HL-60 cells for four hours. Apoptosis was assessed flowcytometrically (occurrence of a sub-Gl peak), by cell morphology (shrinkage) and DNA laddering. ATRA augmented ara-C-induced abundance of cells in the subGl fraction from 8% ± 3% to 16% ± 6% (P < 0.05) as quantified by flow cytometry. ATRA exacerbated ara-Cinduced cell shrinkage by 12% ± 2% (P < 0.01) compared to cells incubated with ara-C alone. Furthermore, ATRA intensified the DNA laddering caused by ara-C (Figure 3 ).
Discussion
The results outlined above demonstrate that an increase in ara-CTP levels is not a mechanistic prerequisite of sensitisation of cells towards ara-C. At ara-C concentrations reached during intermediate and high-dose ara-C strategies, the retinoids increased ara-C-induced cytotoxicity, but decreased ara-CTP levels. This contrasts with the augmentation of ara-C cytotoxicity by ribonucleotide reductase inhibitors which is accompanied by, and mechanistically related to, an elevation of cellular ara-CTP levels [12, 15, 16] . The similarity in effect of the two retinoids ATRA and 13-cz.s-retinoic acid on ara-CTP levels might be related to the chemicallyinduced isomerisation of retinoic acids which occurs under cell culture conditions [40] . The results of this study are consistent with the recent observation that the non-specific protein kinase inhibitor staurosporine sensitised cells towards ara-C without increasing ara-CTP [41] . The observations described above underline the potential usefulness of retinoids as modulators of ara-C efficacy and point to a potential role for ATRA as a chemosensitiser in AML treatment. Interference of retinoids with cellular signalling may be related to their ability to augment ara-C cytotoxicity. ATRA increased ara-C-induced apoptosis, which is consistent with the finding that ara-C sensitisation by ATRA involves downregulation of expression of the antiapoptotic protooncogen bcl-2 [28, 29] .
Further mechanisms of decrease of ara-CTP are considerable: e.g., maturation and differentiation of HL-60 cells resulting in lower activities of the ara-CTP generating enzymes; or upregulation of the ara-CTP diminishing cytidine deaminase as described for DMSO-induced cell differentiation [42] .
In conclusion, the results underline the feasibility of enhancing ara-C efficacy via strategies other than those which increase ara-CTP levels. Preliminary clinical trials of combinations of ara-C with ATRA in the treatment of acute leukemias are promising [26, 27] . In the light of the relatively low toxicity profile of ATRA its combination with ara-C might be worthy of further exploration.
